Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

PROTECT

Financiado

PReparing for Optimal Phase III/IV maTErnal Group B StreptococCal vaccine Trials...

PReparing for Optimal Phase III/IV maTErnal Group B StreptococCal vaccine Trials in Africa (PROTECT) Two vaccines designed for pregnant women, to protect their unborn infant, are entering late phase development and will prevent infections from group B Streptococcus and respiratory syncytial virus, respectively. For these vaccines... ver más

28/02/2027

FUNDACION PRIVADA...

3M€

Presupuesto del proyecto: 3M€

Líder del proyecto

FUNDACION PRIVADA INSTITUTO DE SALUD GLOBAL B... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5 | 27M€

Ver 13 Participantes

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-02-27

HORIZON-JU-GH-EDCTP3-2023-01-03: Implementation research/real life a... ExpectedOutcome:This topic aims at supporting activities that contribute to one or several of the ex...

I+D

Cerrada hace 1 año

0% 100%

13 Participantes

FUNDACION PRIVADA INSTITUTO...

618.06K€ | Lider

UANTWERPEN

108.75K€ | Participante

705.25K€ | Participante

KAMUZU UNIVERSITY OF HEALTH...

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

BFU2015-70052-R BUSQUEDA Y DESARROLLO DE NUEVAS APROXIMACIONES PREVENTIVAS Y... 145K€ Cerrado

CPP2021-008459 AmpliSens. Pruebas rápidas de características mejoradas para... 180K€ Cerrado

FIT-BI Fully Integrated Technology for rapid and multiplex Bacteria... 212K€ Cerrado

SAF2009-11632 ESTRUCTURA-FUNCION DE PROTEINAS DE LOS NEUMOVIRUS QUE REPRES... 456K€ Cerrado

END-VOC ENDING COVID 19 VARIANTS OF CONCERN THROUGH COHORT STUDIES:... 10M€ Cerrado

CPP2021-008310 Interrelación del microbioma y la inmunidad entrenada para e... 395K€ Cerrado

Duración del proyecto: 36 meses Fecha Inicio: 2024-02-27
Fecha Fin: 2027-02-28

Líder del proyecto

FUNDACION PRIVADA INSTITUTO DE SALUD GLOBAL B... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5 | 27M€

Presupuesto del proyecto 3M€

Descripción del proyecto Two vaccines designed for pregnant women, to protect their unborn infant, are entering late phase development and will prevent infections from group B Streptococcus and respiratory syncytial virus, respectively. For these vaccines to be approved, the vaccine must work effectively without causing any unwanted responses. To implement these vaccines in countries with low resources, healthcare systems must be strengthened by improving vaccine safety monitoring and surveillance of infection, and advancing vaccine delivery, vaccine confidence, and patient participation. The rapid rollout of electronic health records (EHR) in Kenya, Mozambique, Malawi, and Uganda offers an opportunity to use routine data to strengthen reporting of rates of adverse pregnancy, neonatal and infant outcomes, and any adverse events following immunisation; this will be imperative in informing and preparing for future large scale vaccination rollout campaigns. Our approach will address key gaps in EHR to develop pregnancy registries embedded within national reporting systems to establish this data, including baseline rates of pregnancy and infancy outcomes for Tetanus and COVID19 vaccines currently in use. These reporting systems will allow monitoring of potential safety signals once new vaccines are introduced. Experts in EHR, obstetrics and gynaecology, paediatrics, microbiology, clinical trials, and implementation research will develop the motivation and tools needed to monitor and evaluate current and future maternal vaccines. We will work closely with the WHO, African Medicines Agency and Country Stakeholders, co-developing pregnancy registries, sentinel site microbiological surveillance systems, and maternal vaccination communications toolkits in preparation for the decade of maternal vaccines. Our programme of work culminates in a network of maternal vaccine trial sites who can rapidly evaluate vaccines in pregnancy from late-stage trials through to introduction on a national level.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores